Interventional Oncology Market - Global Forecast to 2029

Table of Content

1 INTRODUCTION 38
1.1 STUDY OBJECTIVES 38
1.2 MARKET DEFINITION & SCOPE 38
1.2.1 INCLUSIONS & EXCLUSIONS 39
1.2.2 MARKETS COVERED 40
1.2.3 YEARS CONSIDERED 41
1.2.4 CURRENCY CONSIDERED 41
1.3 STAKEHOLDERS 42
1.4 LIMITATIONS 42
1.5 SUMMARY OF CHANGES 42
2 RESEARCH METHODOLOGY 44
2.1 RESEARCH DATA 44
2.1.1 SECONDARY DATA 45
2.1.1.1 Key data from secondary sources 46
2.1.2 PRIMARY DATA 47
2.1.2.1 Key data from primary sources 48
2.1.2.2 Key industry insights 49
2.2 MARKET SIZE ESTIMATION 51
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 57
2.4 MARKET SHARE ESTIMATION 58
2.5 STUDY ASSUMPTIONS 58
2.6 RESEARCH LIMITATIONS 58
2.6.1 METHODOLOGY-RELATED LIMITATIONS 58
2.7 RISK ASSESSMENT 59
3 EXECUTIVE SUMMARY 60
4 PREMIUM INSIGHTS 65
4.1 ATTRACTIVE OPPORTUNITIES FOR PLAYERS IN INTERVENTIONAL ONCOLOGY MARKET 65
4.2 ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES AND COUNTRY, 2023 66
4.3 INTERVENTIONAL ONCOLOGY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 67
4.4 INTERVENTIONAL ONCOLOGY MARKET, BY REGION, 2024?2029 67
4.5 INTERVENTIONAL ONCOLOGY MARKET: DEVELOPED VS. EMERGING MARKETS 68
?
5 MARKET OVERVIEW 69
5.1 INTRODUCTION 69
5.2 MARKET DYNAMICS 69
5.2.1 DRIVERS 70
5.2.1.1 Rising preference for minimally invasive procedures 70
5.2.1.2 Growing prevalence of cancer 70
5.2.1.3 Increasing public-private funding and government support for interventional oncology 71
5.2.1.4 Technological advancements in interventional oncology 71
5.2.2 RESTRAINTS 72
5.2.2.1 High cost of interventional oncology 72
5.2.2.2 Unfavorable regulations 72
5.2.3 OPPORTUNITIES 73
5.2.3.1 Emerging economies offer high-growth potential 73
5.2.4 CHALLENGES 73
5.2.4.1 Dearth of well-trained and skilled radiologists and oncologists 73
5.2.4.2 Strong market position of alternative therapies 74
5.3 INDUSTRY TRENDS 74
5.3.1 INNOVATIONS IN IMAGING AND TREATMENT TECHNOLOGIES 74
5.3.2 INCREASING ADOPTION OF MINIMALLY INVASIVE PROCEDURES 74
5.4 VALUE CHAIN ANALYSIS 75
5.5 TECHNOLOGY ANALYSIS 76
5.5.1 KEY TECHNOLOGIES 76
5.5.1.1 Ablation technologies 76
5.5.1.2 Embolization technologies 76
5.5.2 COMPLEMENTARY TECHNOLOGY 76
5.5.2.1 Laparoscopy 76
5.5.2.2 Diagnostic imaging 76
5.5.3 ADJACENT TECHNOLOGY 77
5.5.3.1 Radiation therapy systems 77
5.5.3.2 Chemotherapy 77
5.6 PORTER’S FIVE FORCES ANALYSIS 77
5.6.1 THREAT OF NEW ENTRANTS 78
5.6.2 THREAT OF SUBSTITUTES 78
5.6.3 BARGAINING POWER OF SUPPLIERS 78
5.6.4 BARGAINING POWER OF BUYERS 78
5.6.5 INTENSITY OF COMPETITIVE RIVALRY 79
5.7 KEY STAKEHOLDERS AND BUYING CRITERIA 79
5.7.1 KEY STAKEHOLDERS IN BUYING PROCESS 79
5.7.2 BUYING CRITERIA 80
?
5.8 REGULATORY LANDSCAPE 81
5.8.1 KEY REGULATORY BODIES AND GOVERNMENT AGENCIES 81
5.8.2 KEY REGULATORY GUIDELINES 84
5.8.2.1 US 84
5.8.2.2 Canada 85
5.8.2.3 Europe 87
5.8.2.4 Asia Pacific 88
5.8.2.4.1 Japan 88
5.8.2.4.2 China 90
5.8.2.4.3 India 91
5.8.2.5 Brazil 92
5.9 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 93
5.10 PATENT ANALYSIS 93
5.10.1 PATENT PUBLICATION TRENDS FOR INTERVENTIONAL ONCOLOGY, JANUARY 2014–DECEMBER 2024 93
5.11 TRADE ANALYSIS 96
5.12 PRICING ANALYSIS 97
5.12.1 AVERAGE SELLING PRICE OF INTERVENTIONAL ONCOLOGY DEVICES,
BY KEY PLAYER, 2023 97
5.12.2 AVERAGE SELLING PRICE OF INTERVENTIONAL ONCOLOGY DEVICES,
BY KEY PLAYER, 2023 (USD) 97
5.12.3 AVERAGE SELLING PRICE TREND OF INTERVENTIONAL ONCOLOGY DEVICES, BY REGION, 2021–2023 98
5.13 KEY CONFERENCES AND EVENTS, 2025–2026 99
5.14 UNMET NEEDS AND END USER EXPECTATIONS 100
5.14.1 UNMET NEEDS 100
5.15 END USER EXPECTATIONS IN INTERVENTIONAL ONCOLOGY MARKET 101
5.16 ECOSYSTEM 102
5.17 CASE STUDIES 103
5.18 SUPPLY CHAIN ANALYSIS 104
5.19 ADJACENT MARKET ANALYSIS 105
5.20 INTERVENTIONAL ONCOLOGY MARKET, INVESTMENT AND FUNDING SCENARIO,
2020–2023 106
5.21 IMPACT OF GENERATIVE AI ON INTERVENTIONAL ONCOLOGY MARKET 106
6 INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES 107
6.1 INTRODUCTION 108
6.2 EMBOLIZATION DEVICES 108
6.2.1 RADIOEMBOLIC AGENTS 112
6.2.1.1 Precision-targeted therapy for challenging liver cancers to boost market 112
?
6.2.2 NON-RADIOACTIVE EMBOLIC AGENTS 115
6.2.2.1 Non-radiation emitting agents to propel market 115
6.2.2.2 Microspheres 119
6.2.2.2.1 Surge in prevalence of hepatocellular carcinoma to fuel growth 119
6.2.2.3 Coated beads 122
6.2.2.3.1 Specialized polymer coatings with enhanced ability to bind, absorb, and release chemotherapeutic agents to drive market 122
6.2.2.4 Microparticles 125
6.2.2.4.1 Use in various cancer applications to drive growth 125
6.3 ABLATION DEVICES 128
6.3.1 RADIOFREQUENCY (RF) ABLATION DEVICES 131
6.3.1.1 Effective treatment of small or difficult-to-reach tumors to propel market growth 131
6.3.2 MICROWAVE ABLATION DEVICES 134
6.3.2.1 Simultaneous treatment of multiple lesions to drive market growth 134
6.3.3 CRYOABLATION DEVICES 137
6.3.3.1 Least painful and higher patient compatibility to drive market 137
6.3.4 OTHER ABLATION DEVICES 140
6.4 SUPPORT DEVICES 143
6.4.1 MICROCATHETERS 146
6.4.1.1 Precise delivery of therapeutic agents to tumors to boost market 146
6.4.2 GUIDEWIRES 149
6.4.2.1 Advancements in guidewire construction and launch of new and advanced products to propel market 149
6.4.3 OTHER SUPPORT DEVICES 151
7 INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE 154
7.1 INTRODUCTION 155
7.2 LIVER CANCER 156
7.2.1 INCREASING DISEASE PREVALENCE AND RISING RESEARCH ACTIVITIES TO DRIVE MARKET GROWTH 156
7.3 KIDNEY CANCER 159
7.3.1 FIRST-LINE THERAPY PRESERVING MORE KIDNEY TISSUE THAN SURGERY TO BOOST MARKET 159
7.4 BREAST CANCER 162
7.4.1 HIGH PRECISION, BETTER COSMETIC OUTCOMES, COST-EFFECTIVENESS, AND GREATER PATIENT COMFORT TO PROPEL MARKET 162
7.5 LUNG CANCER 165
7.5.1 INCREASING NUMBER OF CANCER CASES TO DRIVE DEMAND 165
7.6 BONE CANCER 168
7.6.1 DIRECT ELIMINATION OF TUMORS AND PAIN RELIEF TO FUEL MARKET 168
?
7.7 PROSTATE CANCER 171
7.7.1 RISING INCIDENCE OF PROSTATE CANCER AND GROWING ADOPTION OF METAL-BASED FIDUCIAL MARKERS TO CONTRIBUTE TO MARKET GROWTH 171
7.8 OTHER CANCER TYPES 174
8 INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE 177
8.1 INTRODUCTION 178
8.2 TRANSCATHETER ARTERIAL RADIOEMBOLIZATION/SELECTIVE INTERNAL RADIATION THERAPY (TARE/SIRT) 179
8.2.1 GREATER CLINICAL EFFICACY TO DRIVE MARKET GROWTH 179
8.3 TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION (TACE) 182
8.3.1 ABILITY TO TREAT SMALL AND LARGE-SIZED TUMORS TO DRIVE DEMAND 182
8.4 TRANSCATHETER ARTERIAL EMBOLIZATION/BLAND EMBOLIZATION (TAE) 185
8.4.1 INCREASING CLINICAL EVIDENCE IN FAVOR OF TARE AND TACE TO RESTRAIN MARKET GROWTH 185
8.5 THERMAL TUMOR ABLATION 188
8.5.1 GROWING CLINICAL EVIDENCE PROVING EFFICACY OF TREATMENT OF VARIOUS TYPES OF CANCERS TO DRIVE MARKET GROWTH 188
8.6 NON-THERMAL TUMOR ABLATION 191
8.6.1 POTENTIAL ALTERNATIVE TO THERMAL TUMOR ABLATION TO BOOST MARKET 191
9 INTERVENTIONAL ONCOLOGY MARKET, BY END USER 194
9.1 INTRODUCTION 195
9.2 HOSPITALS 195
9.2.1 INCREASING NUMBER OF SURGERIES IN IN-PATIENT SETTINGS TO SUPPORT MARKET GROWTH 195
9.3 SPECIALTY CLINICS 199
9.3.1 INCREASING NUMBER OF CANCER CENTERS TO DRIVE MARKET GROWTH 199
9.4 RESEARCH & ACADEMIC INSTITUTES 202
9.4.1 COLLABORATIONS AMONG DEVICE MANUFACTURERS AND SUPPLIERS TO FUEL MARKET 202
10 INTERVENTIONAL ONCOLOGY MARKET, BY REGION 205
10.1 INTRODUCTION 206
10.2 NORTH AMERICA 208
10.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 215
10.2.2 US 216
10.2.2.1 Rising cancer cases and preference for ablation procedures to boost market 216
10.2.3 CANADA 223
10.2.3.1 Significant rise in cancer cases to drive market growth 223
?
10.3 EUROPE 229
10.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 238
10.3.2 GERMANY 239
10.3.2.1 Increase in incidence of cancer and rising geriatric population to fuel market 239
10.3.3 UK 245
10.3.3.1 Increasing awareness and support for cancer-related activities to drive market 245
10.3.4 FRANCE 252
10.3.4.1 Growing geriatric population to support market growth 252
10.3.5 SPAIN 258
10.3.5.1 Increasing government funding for research to support market growth 258
10.3.6 ITALY 265
10.3.6.1 Growing awareness about cancer and treatment options to support market growth 265
10.3.7 REST OF EUROPE 271
10.4 ASIA PACIFIC 278
10.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 287
10.4.2 JAPAN 288
10.4.2.1 Rising geriatric population and universal healthcare reimbursement to drive market 288
10.4.3 CHINA 294
10.4.3.1 Increasing incidence of cancer to drive market 294
10.4.4 INDIA 301
10.4.4.1 Improving research capabilities and expansion of key players to drive market growth 301
10.4.5 AUSTRALIA 307
10.4.5.1 Rising investments in research and awareness campaigns to support market growth 307
10.4.6 SOUTH KOREA 314
10.4.6.1 Rising R&D and promising clinical trials to positively impact market growth 314
10.4.7 REST OF ASIA PACIFIC 320
10.5 LATIN AMERICA 327
10.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 334
10.5.2 BRAZIL 335
10.5.2.1 Rising incidence of cancer and improving healthcare infrastructure to fuel market 335
10.5.3 MEXICO 341
10.5.3.1 Increasing awareness campaigns and rising incidence of cancer to drive market growth 341
10.5.4 REST OF LATIN AMERICA 348
?
10.6 MIDDLE EAST & AFRICA 354
10.6.1 MACROECONOMIC OUTLOOK 361
10.6.2 GCC COUNTRIES 362
10.6.2.1 Broader healthcare modernization initiatives in interventional oncology to drive market 362
10.6.3 REST OF MIDDLE EAST & AFRICA 369
11 COMPETITIVE LANDSCAPE 376
11.1 OVERVIEW 376
11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN, 2021–2024 376
11.3 REVENUE ANALYSIS, 2019?2023 378
11.4 MARKET SHARE ANALYSIS, 2023 379
11.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023 382
11.5.1 STARS 382
11.5.2 EMERGING LEADERS 382
11.5.3 PERVASIVE PLAYERS 382
11.5.4 PARTICIPANTS 382
11.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023 384
11.5.5.1 Company footprint 384
11.5.5.2 Region footprint 385
11.5.5.3 Devices & Consumables footprint 386
11.5.5.4 Cancer type footprint 387
11.5.5.5 Procedure footprint 389
11.5.5.6 End user footprint 390
11.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023 391
11.6.1 PROGRESSIVE COMPANIES 391
11.6.2 DYNAMIC COMPANIES 391
11.6.3 STARTING BLOCKS 391
11.6.4 RESPONSIVE COMPANIES 391
11.6.5 COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES, 2023 393
11.6.5.1 Detailed list of key startups/SMES, 2023 393
11.6.5.2 Competitive benchmarking of key startups/SMEs 393
11.7 VALUATION & FINANCIAL METRICS 394
11.7.1 FINANCIAL METRICS 394
11.7.2 COMPANY VALUATION 394
11.8 BRAND COMPARISON 395
11.9 COMPETITIVE SCENARIO 396
11.9.1 PRODUCT & SERVICE LAUNCHES AND APPROVALS 396
11.9.2 DEALS 396
11.9.3 EXPANSIONS 398
?
12 COMPANY PROFILES 399
12.1 KEY PLAYERS 399
12.1.1 SIEMENS HEALTHINEERS AG (VARIAN MEDICAL SYSTEMS, INC) 399
12.1.1.1 Business overview 399
12.1.1.2 Products/Solutions/Services offered 400
12.1.1.3 Recent developments 401
12.1.1.3.1 Product launches & approvals 401
12.1.1.3.2 Deals 401
12.1.1.4 MnM view 402
12.1.1.4.1 Right to win 402
12.1.1.4.2 Strategic choices 403
12.1.1.4.3 Weaknesses and competitive threats 403
12.1.2 BOSTON SCIENTIFIC CORPORATION 404
12.1.2.1 Business overview 404
12.1.2.2 Products/Solutions/Services offered 405
12.1.2.3 Recent developments 406
12.1.2.3.1 Product launches & approvals 406
12.1.2.3.2 Deals 407
12.1.2.4 MnM view 407
12.1.2.4.1 Right to win 407
12.1.2.4.2 Strategic choices 407
12.1.2.4.3 Weaknesses and competitive threats 407
12.1.3 MEDTRONIC 408
12.1.3.1 Business overview 408
12.1.3.2 Products/Solutions/Services offered 409
12.1.3.3 MnM view 411
12.1.3.3.1 Right to win 411
12.1.3.3.2 Strategic choices 411
12.1.3.3.3 Weaknesses and competitive threats 411
12.1.4 TERUMO CORPORATION 412
12.1.4.1 Business overview 412
12.1.4.2 Products/Solutions/Services offered 413
12.1.4.3 Recent developments 414
12.1.4.3.1 Expansions 414
12.1.4.4 MnM view 414
12.1.4.4.1 Right to win 414
12.1.4.4.2 Strategic choices 414
12.1.4.4.3 Weaknesses and competitive threats 414
?
12.1.5 MERIT MEDICAL SYSTEMS 415
12.1.5.1 Business overview 415
12.1.5.2 Products/Solutions/Services offered 416
12.1.5.3 Recent developments 417
12.1.5.3.1 Expansions 417
12.1.5.4 MnM view 417
12.1.5.4.1 Right to win 417
12.1.5.4.2 Strategic choices 418
12.1.5.4.3 Weaknesses and competitive threats 418
12.1.6 JOHNSON & JOHNSON MEDTECH (ETHICON) 419
12.1.6.1 Business overview 419
12.1.6.2 Products/Solutions/Services offered 420
12.1.7 TELEFLEX INCORPORATED 421
12.1.7.1 Business overview 421
12.1.7.2 Products/Solutions/Services offered 422
12.1.8 ANGIODYNAMICS 423
12.1.8.1 Business overview 423
12.1.8.2 Products/Solutions/Services offered 424
12.1.8.3 Recent developments 425
12.1.8.3.1 Product launches & approvals 425
12.1.9 STRYKER 426
12.1.9.1 Business overview 426
12.1.9.2 Products/Solutions/Services offered 427
12.1.10 IMBIOTECHNOLOGIES LTD. 428
12.1.10.1 Business overview 428
12.1.10.2 Products/Solutions/Services offered 428
12.1.11 COOK 429
12.1.11.1 Business overview 429
12.1.11.2 Products/Solutions/Services offered 429
12.1.12 ICECURE MEDICAL 430
12.1.12.1 Business overview 430
12.1.12.2 Products/Solutions/Services offered 431
12.1.12.3 Recent developments 432
12.1.12.3.1 Product approvals 432
12.1.12.3.2 Deals 432
12.1.13 MEDWAVES, INC. 434
12.1.13.1 Business overview 434
12.1.13.2 Products/Solutions/Services offered 434
12.1.14 PROFOUND MEDICAL 435
12.1.14.1 Business overview 435
12.1.14.2 Products/Solutions/Services offered 435
?
12.1.15 RF MEDICAL CO., LTD. 436
12.1.15.1 Business overview 436
12.1.15.2 Products/Solutions/Services offered 436
12.1.16 MINIMAX MEDICAL LIMITED 437
12.1.16.1 Business overview 437
12.1.16.2 Products/Solutions/Services offered 437
12.1.17 ABK BIOMEDICAL INC. 438
12.1.17.1 Business overview 438
12.1.17.2 Products/Solutions/Services offered 438
12.1.18 OLYMPUS CORPORATION 439
12.1.18.1 Business overview 439
12.1.18.2 Products/Solutions/Services offered 440
12.1.19 SURGNOVA 441
12.1.19.1 Business overview 441
12.1.19.2 Products/Solutions/Services offered 441
12.1.20 STARMED AMERICA 442
12.1.20.1 Business overview 442
12.1.20.2 Products/Solutions/Services offered 442
12.2 OTHER PLAYERS 443
12.2.1 SIRTEX SIR-SPHERES PTY LTD. 443
12.2.2 GUERBET 444
12.2.3 ACCURAY INCORPORATED 445
12.2.4 EMBOLX, INC. 446
12.2.5 SONABLATE CORP. 447
13 APPENDIX 448
13.1 DISCUSSION GUIDE 448
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 452
13.3 CUSTOMIZATION OPTIONS 454
13.4 RELATED REPORTS 454
13.5 AUTHOR DETAILS 455

List of Figures

FIGURE 1 INTERVENTIONAL ONCOLOGY MARKET SEGMENTATION 40
FIGURE 2 RESEARCH DESIGN 44
FIGURE 3 PRIMARY SOURCES 47
FIGURE 4 BREAKDOWN OF INTERVIEWS WITH EXPERTS: SUPPLY-SIDE AND
DEMAND-SIDE PARTICIPANTS 49
FIGURE 5 BREAKDOWN OF INTERVIEWS WITH EXPERTS (SUPPLY SIDE):
BY COMPANY TYPE, DESIGNATION, AND REGION 50
FIGURE 6 BREAKDOWN OF INTERVIEWS WITH EXPERTS (DEMAND SIDE):
BY END USER, DESIGNATION, AND REGION 50
FIGURE 7 SUPPLY-SIDE MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS 51
FIGURE 8 REVENUE SHARE ANALYSIS ILLUSTRATION: SIEMENS HEALTHINEERS AG (2023) 52
FIGURE 9 SUPPLY-SIDE MARKET SIZE ESTIMATION: INTERVENTIONAL
ONCOLOGY MARKET (2023) 53
FIGURE 10 TOP-DOWN APPROACH 53
FIGURE 11 ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND
CHALLENGES (2024–2029) 55
FIGURE 12 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 56
FIGURE 13 DATA TRIANGULATION METHODOLOGY 57
FIGURE 14 EMBOLIZATION DEVICES SEGMENT TO DOMINATE INTERVENTIONAL ONCOLOGY MARKET DURING FORECAST PERIOD (USD MILLION) 60
FIGURE 15 LIVER CANCER TYPE SEGMENT TO LEAD MARKET DURING FORECAST
PERIOD (USD MILLION) 61
FIGURE 16 THERMAL TUMOR ABLATION SEGMENT TO GROW AT HIGHEST CAGR DURING FORECAST PERIOD (USD MILLION) 62
FIGURE 17 HOSPITALS SEGMENT TO DOMINATE INTERVENTIONAL ONCOLOGY MARKET DURING FORECAST PERIOD (USD MILLION) 63
FIGURE 18 NORTH AMERICA ACCOUNTED FOR LARGEST SHARE OF INTERVENTIONAL ONCOLOGY MARKET IN 2023 64
FIGURE 19 GROWING DEMAND FOR INTERVENTIONAL ONCOLOGY TO DRIVE MARKET 65
FIGURE 20 EMBOLIZATION DEVICES ACCOUNTED FOR LARGEST SHARE OF INTERVENTIONAL ONCOLOGY MARKET IN 2023 66
FIGURE 21 CHINA TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD 67
FIGURE 22 NORTH AMERICA TO DOMINATE MARKET DURING FORECAST PERIOD 67
FIGURE 23 EMERGING MARKETS TO REGISTER HIGHER GROWTH RATES
DURING FORECAST PERIOD 68
FIGURE 24 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES IN
INTERVENTIONAL ONCOLOGY MARKET 69
FIGURE 25 VALUE CHAIN ANALYSIS: MAXIMUM VALUE ADDED DURING
MANUFACTURING PHASE 75
FIGURE 26 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF EMBOLIZATION DEVICES, ABLATION DEVICES, AND SUPPORT DEVICES 79
FIGURE 27 KEY BUYING CRITERIA FOR EMBOLIZATION DEVICES, ABLATION DEVICES AND SUPPORT DEVICES 80
FIGURE 28 PREMARKET NOTIFICATION: 510(K) APPROVALS FOR MEDICAL DEVICES 85
FIGURE 29 CANADA: REGULATORY APPROVAL PROCESS FOR MEDICAL DEVICES 86
FIGURE 30 EUROPE: CE APPROVAL PROCESS FOR MEDICAL DEVICES 88
FIGURE 31 REVENUE SHIFT IN INTERVENTIONAL ONCOLOGY MARKET 93
FIGURE 32 PATENT PUBLICATION TRENDS, JANUARY 2014–DECEMBER 2024 93
FIGURE 33 TOP PATENT APPLICANTS AND OWNERS (COMPANIES/INSTITUTES) FOR INTERVENTIONAL ONCOLOGY, JANUARY 2014–DECEMBER 2024 94
FIGURE 34 TOP APPLICANT JURISDICTIONS FOR INTERVENTIONAL ONCOLOGY PATENTS, JANUARY 2014–DECEMBER 2024 94
FIGURE 35 AVERAGE SELLING PRICE OF INTERVENTIONAL ONCOLOGY DEVICES BY KEY PLAYER, 2023 97
FIGURE 36 END USER EXPECTATIONS IN EMBOLIZATION DEVICES, ABLATION DEVICES AND SUPPORT DEVICES 101
FIGURE 37 INTERVENTIONAL ONCOLOGY MARKET: ECOSYSTEM 103
FIGURE 38 INTERVENTIONAL ONCOLOGY MARKET: SUPPLY CHAIN ANALYSIS 105
FIGURE 39 ADJACENT MARKETS TO INTERVENTIONAL ONCOLOGY MARKET 105
FIGURE 40 INVESTMENT/VENTURE CAPITAL SCENARIO IN INTERVENTIONAL ONCOLOGY MARKET, 2020–2023 106
FIGURE 41 CHINA TO GROW AT HIGHEST CAGR IN INTERVENTIONAL ONCOLOGY MARKET DURING FORECAST PERIOD 206
FIGURE 42 NORTH AMERICA: INTERVENTIONAL ONCOLOGY MARKET SNAPSHOT 208
FIGURE 43 EUROPE: INTERVENTIONAL ONCOLOGY MARKET SNAPSHOT 230
FIGURE 44 ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET SNAPSHOT 279
FIGURE 45 REVENUE SHARE ANALYSIS OF KEY PLAYERS IN INTERVENTIONAL
ONCOLOGY MARKET,2019?2023 378
FIGURE 46 INTERVENTIONAL ONCOLOGY MARKET SHARE ANALYSIS, BY KEY PLAYER, 2023 379
FIGURE 47 INTERVENTIONAL ONCOLOGY MARKET: COMPANY EVALUATION MATRIX
(KEY PLAYERS), 2023 383
FIGURE 48 INTERVENTIONAL ONCOLOGY MARKET: COMPANY FOOTPRINT 384
FIGURE 49 INTERVENTIONAL ONCOLOGY MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023 392
FIGURE 50 EV/EBITDA OF KEY VENDORS 394
FIGURE 51 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK
BETA OF KEY VENDORS 394
FIGURE 52 INTERVENTIONAL ONCOLOGY MARKET: COMPARATIVE BRAND ANALYSIS 395
FIGURE 53 SIEMENS HEALTHINEERS AG (VARIAN): COMPANY SNAPSHOT (2024) 400
FIGURE 54 BOSTON SCIENTIFIC CORPORATION: COMPANY SNAPSHOT (2023) 405
FIGURE 55 MEDTRONIC: COMPANY SNAPSHOT (2024) 409
FIGURE 56 TERUMO CORPORATION: COMPANY SNAPSHOT (2024) 413
FIGURE 57 MERIT MEDICAL SYSTEMS: COMPANY SNAPSHOT (2023) 416
FIGURE 58 JOHNSON & JOHNSON MEDTECH (ETHICON): COMPANY SNAPSHOT (2023) 420
FIGURE 59 TELEFLEX INCORPORATED: COMPANY SNAPSHOT (2023) 422
FIGURE 60 ANGIODYNAMICS: COMPANY SNAPSHOT (2024) 424
FIGURE 61 STRYKER: COMPANY SNAPSHOT (2023) 427
FIGURE 62 ICECURE MEDICAL LTD.: COMPANY SNAPSHOT (2023) 431
FIGURE 63 OLYMPUS CORPORATION: COMPANY SNAPSHOT (2024) 440

List of Tables

TABLE 1 STANDARD CURRENCY CONVERSION RATES 41
TABLE 2 RISK ASSESSMENT: INTERVENTIONAL ONCOLOGY MARKET 59
TABLE 3 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF EMBOLIZATION DEVICES, ABLATION DEVICES, AND SUPPORT DEVICES 79
TABLE 4 KEY BUYING CRITERIA FOR EMBOLIZATION DEVICES, ABLATION DEVICES, AND SUPPORT DEVICES 80
TABLE 5 NORTH AMERICA: LIST OF REGULATORY BODIES AND GOVERNMENT AGENCIES 81
TABLE 6 EUROPE: LIST OF REGULATORY BODIES AND GOVERNMENT AGENCIES 81
TABLE 7 ASIA PACIFIC: LIST OF REGULATORY BODIES AND GOVERNMENT AGENCIES 82
TABLE 8 LATIN AMERICA: LIST OF REGULATORY BODIES AND GOVERNMENT AGENCIES 83
TABLE 9 MIDDLE EAST & AFRICA: LIST OF REGULATORY BODIES AND
GOVERNMENT AGENCIES 83
TABLE 10 US FDA: MEDICAL DEVICE CLASSIFICATION 84
TABLE 11 US: MEDICAL DEVICE REGULATORY APPROVAL PROCESS 84
TABLE 12 CANADA: MEDICAL DEVICE REGULATORY APPROVAL PROCESS 85
TABLE 13 JAPAN: PMDA CLASSIFICATION OF ABLATION DEVICES 89
TABLE 14 JAPAN: MEDICAL DEVICE CLASSIFICATION UNDER PHARMACEUTICAL AND MEDICAL DEVICE AGENCY (PMDA) 89
TABLE 15 CHINA: CLASSIFICATION OF MEDICAL DEVICES 90
TABLE 16 INDIA: CDSCO CLASSIFICATION OF ABLATION DEVICES 92
TABLE 17 LIST OF PATENTS IN INTERVENTIONAL ONCOLOGY MARKET, 2021–2024 95
TABLE 18 IMPORT DATA FOR INTERVENTIONAL ONCOLOGY (HS CODE 9018), BY COUNTRY, 2019–2023 (USD THOUSAND) 96
TABLE 19 EXPORT DATA FOR INTERVENTIONAL ONCOLOGY (HS CODE 9018), BY COUNTRY, 2019–2023 (USD THOUSAND) 96
TABLE 20 AVERAGE SELLING PRICE OF INTERVENTIONAL ONCOLOGY DEVICES BY KEY PLAYER, 2023 (USD) 97
TABLE 21 AVERAGE SELLING PRICE TREND OF INTERVENTIONAL ONCOLOGY DEVICES BY REGION, 2021–2023 98
TABLE 22 INTERVENTIONAL ONCOLOGY MARKET: KEY CONFERENCES & EVENTS 2025–2026 99
TABLE 23 END USER EXPECTATIONS FOR EMBOLIZATION DEVICES, ABLATION DEVICES AND SUPPORT DEVICES 101
TABLE 24 INTERVENTIONAL ONCOLOGY MARKET: ECOSYSTEM ANALYSIS 102
TABLE 25 TREATMENT OF HEPATOCELLULAR CARCINOMA WITH ARTERIOPORTAL SHUNTING USING BALLOON-ASSISTED TRANSARTERIAL YTTRIUM-90 RADIATION SEGMENTECTOMY 103
TABLE 26 RADIOFREQUENCY ABLATION ANALYSIS CASE STUDY 104
TABLE 27 UPPER POLE ANGIOMYOLIPOMA (AML) EMBOLIZATION 104
TABLE 28 INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES 2019–2023 (USD MILLION) 108
TABLE 29 INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES 2024–2029 (USD MILLION) 108
TABLE 30 INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2019–2023 (USD MILLION) 109
TABLE 31 INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2024–2029 (USD MILLION) 109
TABLE 32 INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY REGION, 2019–2023 (USD MILLION) 110
TABLE 33 INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY REGION, 2024–2029 (USD MILLION) 111
TABLE 34 RADIOEMBOLIC AGENTS OFFERED BY MAJOR MARKET PLAYERS 112
TABLE 35 INTERVENTIONAL ONCOLOGY MARKET FOR RADIOEMBOLIC AGENTS, BY REGION, 2019–2023 (USD MILLION) 113
TABLE 36 INTERVENTIONAL ONCOLOGY MARKET FOR RADIOEMBOLIC AGENTS, BY REGION, 2024–2029 (USD MILLION) 114
TABLE 37 NON-RADIOACTIVE EMBOLIC AGENTS OFFERED BY MAJOR MARKET PLAYERS 115
TABLE 38 INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE EMBOLIC AGENTS, BY TYPE, 2019–2023 (USD MILLION) 116
TABLE 39 INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE EMBOLIC AGENTS, BY TYPE, 2024–2029 (USD MILLION) 116
TABLE 40 INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE EMBOLIC AGENTS, BY REGION, 2019–2023 (USD MILLION) 117
TABLE 41 INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE EMBOLIC AGENTS, BY REGION, 2024–2029 (USD MILLION) 118
TABLE 42 INTERVENTIONAL ONCOLOGY MARKET FOR MICROSPHERES, BY REGION 2019–2023 (USD MILLION) 120
TABLE 43 INTERVENTIONAL ONCOLOGY MARKET FOR MICROSPHERES, BY REGION 2024–2029 (USD MILLION) 121
TABLE 44 INTERVENTIONAL ONCOLOGY MARKET FOR COATED BEADS, BY REGION 2019–2023 (USD MILLION) 123
TABLE 45 INTERVENTIONAL ONCOLOGY MARKET FOR COATED BEADS, BY REGION 2024–2029 (USD MILLION) 124
TABLE 46 MAJOR BRANDS OF MICROCARRIERS 125
TABLE 47 INTERVENTIONAL ONCOLOGY MARKET FOR MICROPARTICLES, BY REGION 2019–2023 (USD MILLION) 126
TABLE 48 INTERVENTIONAL ONCOLOGY MARKET FOR MICROPARTICLES, BY REGION 2024–2029 (USD MILLION) 127
TABLE 49 INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE 2019–2023 (USD MILLION) 128
TABLE 50 INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE 2024–2029 (USD MILLION) 128
TABLE 51 INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY REGION, 2019–2023 (USD MILLION) 129
TABLE 52 INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY REGION, 2024–2029 (USD MILLION) 130
TABLE 53 RADIOFREQUENCY ABLATION DEVICES OFFERED BY MAJOR MARKET PLAYERS 131
TABLE 54 INTERVENTIONAL ONCOLOGY MARKET FOR RADIOFREQUENCY ABLATION DEVICES, BY REGION, 2019–2023 (USD MILLION) 132
TABLE 55 INTERVENTIONAL ONCOLOGY MARKET FOR RADIOFREQUENCY ABLATION DEVICES, BY REGION, 2024–2029 (USD MILLION) 133
TABLE 56 RADIOFREQUENCY ABLATION SYSTEMS, BY REGION 2023–2029 (THOUSAND UNITS) 134
TABLE 57 INTERVENTIONAL ONCOLOGY MARKET FOR MICROWAVE ABLATION DEVICES BY REGION, 2019–2023 (USD MILLION) 135
TABLE 58 INTERVENTIONAL ONCOLOGY MARKET FOR MICROWAVE ABLATION DEVICES BY REGION, 2024–2029 (USD MILLION) 136
TABLE 59 MICROWAVE ABLATION SYSTEMS, BY REGION, 2023–2029 (THOUSAND UNITS) 137
TABLE 60 INTERVENTIONAL ONCOLOGY MARKET FOR CRYOABLATION DEVICES, BY REGION, 2019–2023 (USD MILLION) 138
TABLE 61 INTERVENTIONAL ONCOLOGY MARKET FOR CRYOABLATION DEVICES, BY REGION, 2024–2029 (USD MILLION) 139
TABLE 62 INTERVENTIONAL ONCOLOGY MARKET FOR OTHER ABLATION DEVICES BY REGION, 2019–2023 (USD MILLION) 141
TABLE 63 INTERVENTIONAL ONCOLOGY MARKET FOR OTHER ABLATION DEVICES BY REGION, 2024–2029 (USD MILLION) 142
TABLE 64 INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE 2019–2023 (USD MILLION) 143
TABLE 65 INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE 2024–2029 (USD MILLION) 143
TABLE 66 INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY REGION, 2019–2023 (USD MILLION) 144
TABLE 67 INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY REGION, 2024–2029 (USD MILLION) 145
TABLE 68 INTERVENTIONAL ONCOLOGY MARKET FOR MICROCATHETERS, BY REGION 2019–2023 (USD MILLION) 147
TABLE 69 INTERVENTIONAL ONCOLOGY MARKET FOR MICROCATHETERS, BY REGION 2024–2029 (USD MILLION) 148
TABLE 70 INTERVENTIONAL ONCOLOGY MARKET FOR GUIDEWIRES, BY REGION 2019–2023 (USD MILLION) 150
TABLE 71 INTERVENTIONAL ONCOLOGY MARKET FOR GUIDEWIRES, BY REGION 2024–2029 (USD MILLION) 151
TABLE 72 INTERVENTIONAL ONCOLOGY MARKET FOR OTHER SUPPORT DEVICES BY REGION, 2019–2023 (USD MILLION) 152
TABLE 73 INTERVENTIONAL ONCOLOGY MARKET FOR OTHER SUPPORT DEVICES BY REGION, 2024–2029 (USD MILLION) 153
TABLE 74 INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE 2019–2023 (USD MILLION) 155
TABLE 75 INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE 2024–2029 (USD MILLION) 155
TABLE 76 INTERVENTIONAL ONCOLOGY MARKET FOR LIVER CANCER, BY REGION 2019–2023 (USD MILLION) 157
TABLE 77 INTERVENTIONAL ONCOLOGY MARKET FOR LIVER CANCER, BY REGION 2024–2029 (USD MILLION) 158
TABLE 78 INTERVENTIONAL ONCOLOGY MARKET FOR KIDNEY CANCER, BY REGION 2019–2023 (USD MILLION) 160
TABLE 79 INTERVENTIONAL ONCOLOGY MARKET FOR KIDNEY CANCER, BY REGION 2024–2029 (USD MILLION) 161
TABLE 80 INTERVENTIONAL ONCOLOGY MARKET FOR BREAST CANCER, BY REGION 2019–2023 (USD MILLION) 163
TABLE 81 INTERVENTIONAL ONCOLOGY MARKET FOR BREAST CANCER, BY REGION 2024–2029 (USD MILLION) 164
TABLE 82 INTERVENTIONAL ONCOLOGY MARKET FOR LUNG CANCER, BY REGION 2019–2023 (USD MILLION) 166
TABLE 83 INTERVENTIONAL ONCOLOGY MARKET FOR LUNG CANCER, BY REGION 2024–2029 (USD MILLION) 167
TABLE 84 INTERVENTIONAL ONCOLOGY MARKET FOR BONE CANCER, BY REGION 2019–2023 (USD MILLION) 169
TABLE 85 INTERVENTIONAL ONCOLOGY MARKET FOR BONE CANCER, BY REGION 2024–2029 (USD MILLION) 170
TABLE 86 INTERVENTIONAL ONCOLOGY MARKET FOR PROSTATE CANCER, BY REGION, 2019–2023 (USD MILLION) 172
TABLE 87 INTERVENTIONAL ONCOLOGY MARKET FOR PROSTATE CANCER, BY REGION, 2024–2029 (USD MILLION) 173
TABLE 88 INTERVENTIONAL ONCOLOGY MARKET FOR OTHER CANCER TYPES, BY REGION, 2019–2023 (USD MILLION) 175
TABLE 89 INTERVENTIONAL ONCOLOGY MARKET FOR OTHER CANCER TYPES, BY REGION, 2024–2029 (USD MILLION) 176
TABLE 90 INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE 2019–2023 (USD MILLION) 178
TABLE 91 INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE 2024–2029 (USD MILLION) 178
TABLE 92 INTERVENTIONAL ONCOLOGY MARKET FOR TRANSCATHETER ARTERIAL RADIOEMBOLIZATION/SELECTIVE INTERNAL RADIATION THERAPY (TARE/SIRT) BY REGION, 2019–2023 (USD MILLION) 180
TABLE 93 INTERVENTIONAL ONCOLOGY MARKET FOR TRANSCATHETER ARTERIAL RADIOEMBOLIZATION/SELECTIVE INTERNAL RADIATION THERAPY (TARE/SIRT) BY REGION, 2024–2029 (USD MILLION) 181
TABLE 94 INTERVENTIONAL ONCOLOGY MARKET FOR TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION (TACE), BY REGION, 2019–2023 (USD MILLION) 183
TABLE 95 INTERVENTIONAL ONCOLOGY MARKET FOR TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION (TACE), BY REGION, 2024–2029 (USD MILLION) 184
TABLE 96 INTERVENTIONAL ONCOLOGY MARKET FOR TRANSCATHETER ARTERIAL EMBOLIZATION/BLAND EMBOLIZATION (TAE), BY REGION 2019–2023 (USD MILLION) 186
TABLE 97 INTERVENTIONAL ONCOLOGY MARKET FOR TRANSCATHETER ARTERIAL EMBOLIZATION/BLAND EMBOLIZATION (TAE), BY REGION 2024–2029 (USD MILLION) 187
TABLE 98 INTERVENTIONAL ONCOLOGY MARKET FOR THERMAL TUMOR ABLATION BY REGION, 2019–2023 (USD MILLION) 189
TABLE 99 INTERVENTIONAL ONCOLOGY MARKET FOR THERMAL TUMOR ABLATION BY REGION, 2024–2029 (USD MILLION) 190
TABLE 100 INTERVENTIONAL ONCOLOGY MARKET FOR NON-THERMAL TUMOR ABLATION BY REGION, 2019–2023 (USD MILLION) 192
TABLE 101 INTERVENTIONAL ONCOLOGY MARKET FOR NON-THERMAL TUMOR ABLATION BY REGION, 2024–2029 (USD MILLION) 193
TABLE 102 INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2019–2023 (USD MILLION) 195
TABLE 103 INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2024–2029 (USD MILLION) 195
TABLE 104 INTERVENTIONAL ONCOLOGY MARKET FOR HOSPITALS, BY REGION 2019–2023 (USD MILLION) 197
TABLE 105 INTERVENTIONAL ONCOLOGY MARKET FOR HOSPITALS, BY REGION 2024–2029 (USD MILLION) 198
TABLE 106 INTERVENTIONAL ONCOLOGY MARKET FOR SPECIALTY CLINICS, BY REGION, 2019–2023 (USD MILLION) 200
TABLE 107 INTERVENTIONAL ONCOLOGY MARKET FOR SPECIALTY CLINICS, BY REGION, 2024–2029 (USD MILLION) 201
TABLE 108 INTERVENTIONAL ONCOLOGY MARKET FOR RESEARCH & ACADEMIC INSTITUTES, BY REGION, 2019–2023 (USD MILLION) 203
TABLE 109 INTERVENTIONAL ONCOLOGY MARKET FOR RESEARCH & ACADEMIC INSTITUTES, BY REGION, 2024–2029 (USD MILLION) 204
TABLE 110 INTERVENTIONAL ONCOLOGY MARKET, BY REGION, 2019–2023 (USD MILLION) 207
TABLE 111 INTERVENTIONAL ONCOLOGY MARKET, BY REGION, 2024–2029 (USD MILLION) 207
TABLE 112 NORTH AMERICA: INTERVENTIONAL ONCOLOGY MARKET, BY COUNTRY 2019–2023 (USD MILLION) 209
TABLE 113 NORTH AMERICA: INTERVENTIONAL ONCOLOGY MARKET, BY COUNTRY 2024–2029 (USD MILLION) 209
TABLE 114 NORTH AMERICA: INTERVENTIONAL ONCOLOGY MARKET BY DEVICES & CONSUMABLES, 2019–2023 (USD MILLION) 209
TABLE 115 NORTH AMERICA: INTERVENTIONAL ONCOLOGY MARKET BY DEVICES & CONSUMABLES, 2024–2029 (USD MILLION) 210
TABLE 116 NORTH AMERICA: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2019–2023 (USD MILLION) 210
TABLE 117 NORTH AMERICA: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2024–2029 (USD MILLION) 210
TABLE 118 NORTH AMERICA: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2019–2023 (USD MILLION) 211
TABLE 119 NORTH AMERICA: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2024–2029 (USD MILLION) 211
TABLE 120 NORTH AMERICA: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2019–2023 (USD MILLION) 211
TABLE 121 NORTH AMERICA: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2024–2029 (USD MILLION) 212
TABLE 122 NORTH AMERICA: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2023 (USD MILLION) 212
TABLE 123 NORTH AMERICA: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2024–2029 (USD MILLION) 212
TABLE 124 NORTH AMERICA: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE 2019–2023 (USD MILLION) 213
TABLE 125 NORTH AMERICA: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE 2024–2029 (USD MILLION) 213
TABLE 126 NORTH AMERICA: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE 2019–2023 (USD MILLION) 214
TABLE 127 NORTH AMERICA: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE 2024–2029 (USD MILLION) 214
TABLE 128 NORTH AMERICA: INTERVENTIONAL ONCOLOGY MARKET, BY END USER 2019–2023 (USD MILLION) 215
TABLE 129 NORTH AMERICA: INTERVENTIONAL ONCOLOGY MARKET, BY END USER 2024–2029 (USD MILLION) 215
TABLE 130 US: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES 2019–2023 (USD MILLION) 217
TABLE 131 US: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES 2024–2029 (USD MILLION) 217
TABLE 132 US: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2019–2023 (USD MILLION) 217
TABLE 133 US: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2024–2029 (USD MILLION) 218
TABLE 134 US: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS BY TYPE, 2019–2023 (USD MILLION) 218
TABLE 135 US: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS BY TYPE, 2024–2029 (USD MILLION) 218
TABLE 136 US: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2019–2023 (USD MILLION) 219
TABLE 137 US: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2024–2029 (USD MILLION) 219
TABLE 138 US: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2023 (USD MILLION) 219
TABLE 139 US: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2024–2029 (USD MILLION) 220
TABLE 140 US: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE 2019–2023 (USD MILLION) 220
TABLE 141 US: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE 2024–2029 (USD MILLION) 221
TABLE 142 US: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE 2019–2023 (USD MILLION) 221
TABLE 143 US: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE 2024–2029 (USD MILLION) 222
TABLE 144 US: INTERVENTIONAL ONCOLOGY MARKET, BY END USER 2019–2023 (USD MILLION) 222
TABLE 145 US: INTERVENTIONAL ONCOLOGY MARKET, BY END USER 2024–2029 (USD MILLION) 222
TABLE 146 CANADA: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2019–2023 (USD MILLION) 223
TABLE 147 CANADA: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2024–2029 (USD MILLION) 224
TABLE 148 CANADA: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES BY TYPE, 2019–2023 (USD MILLION) 224
TABLE 149 CANADA: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES BY TYPE, 2024–2029 (USD MILLION) 224
TABLE 150 CANADA: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2019–2023 (USD MILLION) 225
TABLE 151 CANADA: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2024–2029 (USD MILLION) 225
TABLE 152 CANADA: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2019–2023 (USD MILLION) 225
TABLE 153 CANADA: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2024–2029 (USD MILLION) 226
TABLE 154 CANADA: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2023 (USD MILLION) 226
TABLE 155 CANADA: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2024–2029 (USD MILLION) 226
TABLE 156 CANADA: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE 2019–2023 (USD MILLION) 227
TABLE 157 CANADA: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE 2024–2029 (USD MILLION) 227
TABLE 158 CANADA: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE 2019–2023 (USD MILLION) 228
TABLE 159 CANADA: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE 2024–2029 (USD MILLION) 228
TABLE 160 CANADA: INTERVENTIONAL ONCOLOGY MARKET, BY END USER 2019–2023 (USD MILLION) 229
TABLE 161 CANADA: INTERVENTIONAL ONCOLOGY MARKET, BY END USER 2024–2029 (USD MILLION) 229
TABLE 162 EUROPE: INTERVENTIONAL ONCOLOGY MARKET, BY COUNTRY 2019–2023 (USD MILLION) 231
TABLE 163 EUROPE: INTERVENTIONAL ONCOLOGY MARKET, BY COUNTRY 2024–2029 (USD MILLION) 231
TABLE 164 EUROPE: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2019–2023 (USD MILLION) 232
TABLE 165 EUROPE: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2024–2029 (USD MILLION) 232
TABLE 166 EUROPE: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES BY TYPE, 2019–2023 (USD MILLION) 232
TABLE 167 EUROPE: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES BY TYPE, 2024–2029 (USD MILLION) 233
TABLE 168 EUROPE: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2019–2023 (USD MILLION) 233
TABLE 169 EUROPE: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2024–2029 (USD MILLION) 233
TABLE 170 EUROPE: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2019–2023 (USD MILLION) 234
TABLE 171 EUROPE: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2024–2029 (USD MILLION) 234
TABLE 172 EUROPE: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2023 (USD MILLION) 234
TABLE 173 EUROPE: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2024–2029 (USD MILLION) 235
TABLE 174 EUROPE: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE 2019–2023 (USD MILLION) 235
TABLE 175 EUROPE: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE 2024–2029 (USD MILLION) 236
TABLE 176 EUROPE: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE 2019–2023 (USD MILLION) 236
TABLE 177 EUROPE: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE 2024–2029 (USD MILLION) 237
TABLE 178 EUROPE: INTERVENTIONAL ONCOLOGY MARKET, BY END USER 2019–2023 (USD MILLION) 237
TABLE 179 EUROPE: INTERVENTIONAL ONCOLOGY MARKET, BY END USER 2024–2029 (USD MILLION) 238
TABLE 180 GERMANY: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2019–2023 (USD MILLION) 239
TABLE 181 GERMANY: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2024–2029 (USD MILLION) 240
TABLE 182 GERMANY: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2019–2023 (USD MILLION) 240
TABLE 183 GERMANY: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2024–2029 (USD MILLION) 240
TABLE 184 GERMANY: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2019–2023 (USD MILLION) 241
TABLE 185 GERMANY: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2024–2029 (USD MILLION) 241
TABLE 186 GERMANY: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES BY TYPE, 2019–2023 (USD MILLION) 241
TABLE 187 GERMANY: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES BY TYPE, 2024–2029 (USD MILLION) 242
TABLE 188 GERMANY: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES BY TYPE, 2019–2023 (USD MILLION) 242
TABLE 189 GERMANY: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES BY TYPE, 2024–2029 (USD MILLION) 242
TABLE 190 GERMANY: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE 2019–2023 (USD MILLION) 243
TABLE 191 GERMANY: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE 2024–2029 (USD MILLION) 243
TABLE 192 GERMANY: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE 2019–2023 (USD MILLION) 244
TABLE 193 GERMANY: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE 2024–2029 (USD MILLION) 244
TABLE 194 GERMANY: INTERVENTIONAL ONCOLOGY MARKET, BY END USER 2019–2023 (USD MILLION) 245
TABLE 195 GERMANY: INTERVENTIONAL ONCOLOGY MARKET, BY END USER 2024–2029 (USD MILLION) 245
TABLE 196 UK: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES 2019–2023 (USD MILLION) 246
TABLE 197 UK: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES 2024–2029 (USD MILLION) 246
TABLE 198 UK: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2019–2023 (USD MILLION) 246
TABLE 199 UK: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2024–2029 (USD MILLION) 247
TABLE 200 UK: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS BY TYPE, 2019–2023 (USD MILLION) 247
TABLE 201 UK: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS BY TYPE, 2024–2029 (USD MILLION) 247
TABLE 202 UK: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2019–2023 (USD MILLION) 248
TABLE 203 UK: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2024–2029 (USD MILLION) 248
TABLE 204 UK: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2023 (USD MILLION) 248
TABLE 205 UK: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2024–2029 (USD MILLION) 249
TABLE 206 UK: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE 2019–2023 (USD MILLION) 249
TABLE 207 UK: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE 2024–2029 (USD MILLION) 250
TABLE 208 UK: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE 2019–2023 (USD MILLION) 250
TABLE 209 UK: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE 2024–2029 (USD MILLION) 251
TABLE 210 UK: INTERVENTIONAL ONCOLOGY MARKET, BY END USER 2019–2023 (USD MILLION) 251
TABLE 211 UK: INTERVENTIONAL ONCOLOGY MARKET, BY END USER 2024–2029 (USD MILLION) 251
TABLE 212 FRANCE: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2019–2023 (USD MILLION) 252
TABLE 213 FRANCE: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2024–2029 (USD MILLION) 253
TABLE 214 FRANCE: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES BY TYPE, 2019–2023 (USD MILLION) 253
TABLE 215 FRANCE: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES BY TYPE, 2024–2029 (USD MILLION) 253
TABLE 216 FRANCE: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2019–2023 (USD MILLION) 254
TABLE 217 FRANCE: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2024–2029 (USD MILLION) 254
TABLE 218 FRANCE: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2019–2023 (USD MILLION) 254
TABLE 219 FRANCE: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2024–2029 (USD MILLION) 255
TABLE 220 FRANCE: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2023 (USD MILLION) 255
TABLE 221 FRANCE: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2024–2029 (USD MILLION) 255
TABLE 222 FRANCE: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE 2019–2023 (USD MILLION) 256
TABLE 223 FRANCE: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE 2024–2029 (USD MILLION) 256
TABLE 224 FRANCE: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE 2019–2023 (USD MILLION) 257
TABLE 225 FRANCE: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE 2024–2029 (USD MILLION) 257
TABLE 226 FRANCE: INTERVENTIONAL ONCOLOGY MARKET, BY END USER 2019–2023 (USD MILLION) 258
TABLE 227 FRANCE: INTERVENTIONAL ONCOLOGY MARKET, BY END USER 2024–2029 (USD MILLION) 258
TABLE 228 SPAIN: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2019–2023 (USD MILLION) 259
TABLE 229 SPAIN: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2024–2029 (USD MILLION) 259
TABLE 230 SPAIN: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES BY TYPE, 2019–2023 (USD MILLION) 259
TABLE 231 SPAIN: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES BY TYPE, 2024–2029 (USD MILLION) 260
TABLE 232 SPAIN: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS BY TYPE, 2019–2023 (USD MILLION) 260
TABLE 233 SPAIN: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS BY TYPE, 2024–2029 (USD MILLION) 260
TABLE 234 SPAIN: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2019–2023 (USD MILLION) 261
TABLE 235 SPAIN: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2024–2029 (USD MILLION) 261
TABLE 236 SPAIN: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2023 (USD MILLION) 261
TABLE 237 SPAIN: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2024–2029 (USD MILLION) 262
TABLE 238 SPAIN: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE 2019–2023 (USD MILLION) 262
TABLE 239 SPAIN: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE 2024–2029 (USD MILLION) 263
TABLE 240 SPAIN: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE 2019–2023 (USD MILLION) 263
TABLE 241 SPAIN: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE 2024–2029 (USD MILLION) 264
TABLE 242 SPAIN: INTERVENTIONAL ONCOLOGY MARKET, BY END USER 2019–2023 (USD MILLION) 264
TABLE 243 SPAIN: INTERVENTIONAL ONCOLOGY MARKET, BY END USER 2024–2029 (USD MILLION) 264
TABLE 244 ITALY: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2019–2023 (USD MILLION) 265
TABLE 245 ITALY: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2024–2029 (USD MILLION) 266
TABLE 246 ITALY: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES BY TYPE, 2019–2023 (USD MILLION) 266
TABLE 247 ITALY: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES BY TYPE, 2024–2029 (USD MILLION) 266
TABLE 248 ITALY: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS BY TYPE, 2019–2023 (USD MILLION) 267
TABLE 249 ITALY: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS BY TYPE, 2024–2029 (USD MILLION) 267
TABLE 250 ITALY: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2019–2023 (USD MILLION) 267
TABLE 251 ITALY: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2024–2029 (USD MILLION) 268
TABLE 252 ITALY: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2023 (USD MILLION) 268
TABLE 253 ITALY: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2024–2029 (USD MILLION) 268
TABLE 254 ITALY: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE 2019–2023 (USD MILLION) 269
TABLE 255 ITALY: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE 2024–2029 (USD MILLION) 269
TABLE 256 ITALY: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE 2019–2023 (USD MILLION) 270
TABLE 257 ITA